Clémence Thébaut

Clémence Thébaut
University of Limoges | UNILIM · Pôle Management de la Santé

PhD

About

22
Publications
1,998
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
41
Citations
Additional affiliations
January 2008 - September 2015
Haute Autorité de Santé
Position
  • Project Manager

Publications

Publications (22)
Article
Objective Systematic reviews were conducted on the existence of screening tools for epilepsy, quality of life or comorbidities tools, but not specifically in low- and middle-income countries. This study aimed to identify the different tools developed and validated in low- and middle-income countries for the investigation of epilepsy. This to facili...
Conference Paper
Full-text available
Objective: To review studies conducted on the costs of dementia in low- and middle-income countries (LMICs), describe their methodology and summarize costs estimates.
Article
Full-text available
Background: Epilepsy affects more than 50 million people worldwide, 80% of whom live in low- and middle-income countries (LMICs). In Southeast Asia, the prevalence is moderate (6‰), and the main public health challenge is reducing the treatment gap, which reaches more than 90% in rural areas. Methods: This 12-month comparative study (intervention v...
Article
Background Diseases consequence on individual work as much as consequences of being absent from work are matters of interest for decision makers. Methods We analyzed lengths of absenteeism and related indirect costs for patients with a paid activity in the year following the diagnosis of early stage breast cancer, in the prospective OPTISOINS01 co...
Preprint
Full-text available
Introduction: The consequences of disease on work for individual patients as well as the consequences of absenteeism from work are subjects of interest for decision-makers. Methods: We analyzed duration of absenteeism and related indirect costs for patients with a paid job during the year following diagnosis of early-stage breast cancer in the pros...
Article
Depuis 2012, en France, les industries pharmaceutiques qui sollicitent l’admission au remboursement pour un traitement innovant sont contraintes de soumettre une évaluation économique auprès de la Commission d’évaluation économique et de santé publique (CEESP) de la Haute Autorité de santé (HAS) afin qu’un avis sur son efficience puisse être rendu....
Article
Full-text available
We evaluate the introduction of various forms of antihypertensive treatments in France with a distribution-sensitive cost-benefit analysis. Compared to traditional cost-benefit analysis, we implement distributional weighting based on equivalent incomes, a new concept of individual well-being that does respect individual preferences but is not subje...
Research
Full-text available
A la demande de la Direction Générale de la Santé, la HAS a réalisé un état des connaissances sur la situation sanitaire des personnes en situation de prostitution/travailleurs du sexe et sur leurs facteurs de vulnérabilité sanitaire. Ce rapport comporte également une synthèse des recommandations de bonnes pratiques sur les infections sexuellement...
Article
The economic evaluation of innovative health products: how is it interpreted and for what purpose? The 2012 law for financing the social security system (LFSS) introduced the criterion of efficiency in setting the prices of innovative health products. The implementation of this provision by the High Authority for Health (HAS) and the Economic Commi...
Article
Since 3rd October 2013 in France, drug companies applying for reimbursement of an innovative and expensive drug or medical device are required to provide the French National Authority for Health (HAS) with a cost-effectiveness assessment of their product. After a methodological audit of the economic evaluation submitted by the drug company, the Hea...
Article
Haute Autorité de santé opinion on cost-effectiveness of health products : results and perspectives Since 3rd October 2013 in France, drug companies applying for reimbursement of an innovative and expensive drug or medical device are required to provide the French National Authority for Health (HAS) with a cost-effectiveness assessment of their pro...
Article
We compare two approaches to measuring inequity in the health distribution. The first is the concentration index. The second is the calculation of the inequality in an overall measure of individual well-being, capturing both the income and health dimensions. We introduce the concept of equivalent income as a measure of well-being that respects pref...
Article
The aim of this article is to assess dilemma raised by adaptive preferences in the economic evaluation of growth hormone (GH) treatment for non-GH-deficient short children, and of bilateral cochlear implants for deaf children. Early implementation of both technologies and their irreversible consequences increase the potential conflicts faced by the...
Thesis
Full-text available
Welfare economics encompasses other public choice theories besides utilitarianism, like egalitarian social justice theory. Whether these economic frameworks provide practical tools that could be used in health technology assessment is an ongoing debate, and this study aims to contribute to answering this question. The goal of the first chapter is...
Article
Full-text available
Welfare economics encompasses other public choice theories besides utilitarianism, like egalitarian social justice theory. Whether these economic frameworks provide practical tools that could be used in health technology assessment is an ongoing debate, and this study aim to contribute to answer this question. The aim of the first chapter is to rev...
Article
Full-text available
Our objective is to review health economic evaluation guidelines and compare methods from three national health technology assessment agencies - NICE (England and Wales), IQWiG (Germany) and KCE (Belgium) - and to assess how differences in methods may be explained by differences in philosophical views. We constructed a typology based on social choi...

Network

Cited By